Treatment for Influenza B
For influenza B infection, treat with either oseltamivir or zanamivir—these are the only antivirals with activity against influenza B, as adamantanes have no effect on this virus type 1, 2.
Treatment Algorithm by Clinical Severity
Non-Severe Influenza B (Outpatient)
High-risk patients (elderly, pregnant, immunocompromised, chronic medical conditions):
- Initiate oseltamivir or zanamivir within 48 hours of symptom onset 1
- Baloxavir is conditionally recommended for high-risk patients to prevent progression to severe disease 3
- Treatment duration: 5 days (longer courses may be considered if severely ill after 5 days) 2
Low-risk patients:
- Treatment is optional but can reduce illness duration by 1-2.5 days if started within 48 hours 1, 4
- Consider treatment if patient desires symptom reduction or has close contact with high-risk individuals 1
- Do NOT use antibiotics unless bacterial co-infection is confirmed (strong recommendation against empiric antibiotics) 3
Severe Influenza B (Hospitalized)
- Oseltamivir is the primary recommendation 3
- Intravenous zanamivir is available in some countries for hospitalized patients 5
- Peramivir (IV formulation) is an alternative option 5
Avoid these adjunctive therapies in severe influenza:
- Corticosteroids (conditional recommendation against) 3
- Macrolide antibiotics (unless bacterial co-infection documented) 3
- mTOR inhibitors 3
- NSAIDs 3
- Passive immune therapy 3
Specific Dosing Recommendations
Oseltamivir (≥1 year old) 2:
Treatment (twice daily for 5 days):
- ≤15 kg: 30 mg twice daily
15-23 kg: 45 mg twice daily
23-40 kg: 60 mg twice daily
40 kg: 75 mg twice daily
Prophylaxis (once daily):
- Same weight-based dosing as treatment, but once daily
- Duration: 10 days after household exposure, 7 days after other exposures
Zanamivir:
- Inhaled formulation available but less suitable for severe illness or patients with airway disease 5
- More effective against influenza B than some other antivirals 5
Critical Timing Considerations
The 48-hour window is crucial but not absolute:
- Optimal efficacy: within 48 hours of symptom onset 1, 4
- Patients presenting after 48 hours with persistent moderate-to-severe illness may still benefit, though evidence is limited 1
- For severe/hospitalized patients, treat regardless of timing since symptom onset 3
Resistance Patterns
Influenza B has favorable resistance profiles:
- Susceptible to both oseltamivir and zanamivir 2
- Resistance development during treatment is rare (0% in one study vs 27% for H1N1 and 3% for H3N2) 2
- Transmission of resistant strains is uncommon but documented 2
Post-Exposure Prophylaxis
Consider prophylaxis with oseltamivir, zanamivir, baloxavir, or laninamivir for 1, 3:
- Unvaccinated high-risk individuals exposed to confirmed influenza B
- During the 2-week period after vaccination (before immunity develops)
- Healthcare workers and close contacts of high-risk patients
- Outbreak control in institutional settings (minimum 2 weeks, up to 1 week after last case) 2
Common Pitfalls to Avoid
- Do not use adamantanes (amantadine/rimantadine) for influenza B—they have zero activity against this virus type 1, 2
- Do not prescribe empiric antibiotics—strong evidence against this practice unless bacterial co-infection is documented 3
- Do not delay treatment waiting for test results in high-risk patients with clinical influenza during flu season 1
- Do not use corticosteroids as adjunctive therapy—they are not beneficial and potentially harmful 3
- Zanamivir inhaler is problematic for patients with asthma/COPD or severe respiratory compromise 5
Diagnostic Testing Strategy
For optimal treatment decisions, use nucleic acid amplification tests (NAAT) or digital immunoassays (DIA) for rapid, accurate diagnosis to guide time-sensitive antiviral therapy 3, 6.